TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
NNNN

Anbio Biotechnology

Healthcare · Medical Instruments & Supplies

6.10$ -3.3% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Anbio Biotechnology (NNNN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 90.4% of the shares are freely tradable; institutional investors hold 4.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 4.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 4.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 90.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 44Mio.

Largest Shareholders

Institutions

Institutions NNNN
Name Stake (%) Shares Change (%) Date
Geode Capital Management, LLC 0.06 25,763 +0.0 03/31/2026
BNP Paribas Arbitrage, SA 0.02 10,400 +940.0 03/31/2026
Morgan Stanley - Brokerage Accounts 0.02 7,338 +26,107.1 03/31/2026
UBS Group AG 0.01 6,339 +122.5 03/31/2026
EverSource Wealth Advisors, LLC 0.00 187 -29.7 06/30/2026
Wells Fargo & Co 0.00 100 +0.0 03/31/2026

Funds

Funds NNNN
Name Stake (%) Shares Change (%) Date
Fidelity Nasdaq Composite Index 0.06 26,736 +0.0 07/31/2026
Northern Small Cap Core I 0.02 7,140 +0.0 06/30/2026
Invesco Dw Jns Islmc Glb Dev MktsETF$Acc 0.00 35 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?